RESUMEN
BACKGROUND: Asthma is a heterogeneous disease and development of novel therapeutics requires an understanding of pathophysiologic phenotypes. The purpose of the ADEPT study was to correlate clinical features and biomarkers with molecular characteristics, by profiling asthma (NCT01274507). This report presents for the first time the study design, and characteristics of the recruited subjects. METHODS: Patients with a range of asthma severity and healthy non-atopic controls were enrolled. The asthmatic subjects were followed for 12 months. Assessments included history, patient questionnaires, spirometry, airway hyper-responsiveness to methacholine, fractional exhaled nitric oxide (FENO), and biomarkers measured in induced sputum, blood, and bronchoscopy samples. All subjects underwent sputum induction and 30 subjects/cohort had bronchoscopy. RESULTS: Mild (n = 52), moderate (n = 55), severe (n = 51) asthma cohorts and 30 healthy controls were enrolled from North America and Western Europe. Airflow obstruction, bronchodilator response and airways hyperresponsiveness increased with asthma severity, and severe asthma subjects had reduced forced vital capacity. Asthma control questionnaire-7 (ACQ7) scores worsened with asthma severity. In the asthmatics, mean values for all clinical and biomarker characteristics were stable over 12 months although individual variability was evident. FENO and blood eosinophils did not differ by asthma severity. Induced sputum eosinophils but not neutrophils were lower in mild compared to the moderate and severe asthma cohorts. CONCLUSIONS: The ADEPT study successfully enrolled asthmatics across a spectrum of severity and non-atopic controls. Clinical characteristics were related to asthma severity and in general asthma characteristics e.g. lung function, were stable over 12 months. Use of the ADEPT data should prove useful in defining biological phenotypes to facilitate personalized therapeutic approaches.
Asunto(s)
Antiasmáticos/uso terapéutico , Asma/diagnóstico , Asma/tratamiento farmacológico , Broncodilatadores/uso terapéutico , Pulmón/efectos de los fármacos , Medicina de Precisión , Adolescente , Adulto , Anciano , Asma/epidemiología , Asma/metabolismo , Asma/fisiopatología , Biomarcadores/metabolismo , Broncoconstricción/efectos de los fármacos , Canadá/epidemiología , Estudios de Casos y Controles , Europa (Continente)/epidemiología , Femenino , Humanos , Estudios Longitudinales , Pulmón/metabolismo , Pulmón/fisiopatología , Masculino , Persona de Mediana Edad , Selección de Paciente , Fenotipo , Valor Predictivo de las Pruebas , Prevalencia , Proyectos de Investigación , Pruebas de Función Respiratoria , Factores de Riesgo , Índice de Severidad de la Enfermedad , Esputo/metabolismo , Encuestas y Cuestionarios , Factores de Tiempo , Resultado del Tratamiento , Estados Unidos/epidemiología , Adulto JovenRESUMEN
We demonstrate, to the best of our knowledge, a first accurate empirical model for reflectance measurements from highly turbid media over the full range of incident angles, i.e., for reflectivity values going from unity in the total internal reflection regime to nearly zero when almost all the light is transmitted. Evidence that our model is accurate is provided by extraction of the particle size, followed by independent verification with dynamic light scattering. Our methodology is in direct contrast with the prevalent approach in turbid media of focusing on only the critical angle region, which is just a small subset of the entire reflectance data.
Asunto(s)
Luz , Modelos Biológicos , Nefelometría y Turbidimetría/métodos , Refractometría/métodos , Dispersión de Radiación , Animales , Simulación por Computador , HumanosRESUMEN
Peiponen et al. [Opt. Lett.35, 4108 (2010)] have expressed concern that a theoretical model we proposed in Calhoun et al. [Opt. Lett.35, 1224 (2010)] for total internal reflection from a turbid medium may be inconsistent with the experimental data, in the sense that the model fails to take into account unexplained oscillations in our data. We show that their concern arises from misinterpretation of our data and theory, and is, therefore, unfounded. NOTE: Optics Letters apologizes to the authors for the delay in the publication of this Reply.
RESUMEN
Airway remodeling is a central feature of asthma. It is exemplified by thickening of the lamina reticularis and structural changes to the epithelium, submucosa, smooth muscle, and vasculature of the airway wall. Airway remodeling may result from persistent airway inflammation. Immunoglobulin E (IgE) is an important mediator of allergic reactions and has a central role in airway inflammation and asthma-related symptoms. Anti-IgE therapies (such as omalizumab) have the potential to block an early step in the allergic cascade and therefore have the potential to reduce airway remodeling. The reduction in free IgE levels following anti-IgE therapy leads to reductions in high-affinity IgE receptor (FcεRI) expression on mast cells, basophils, and dendritic cells. This combined effect results in attenuation of several markers of inflammation, including peripheral and bronchial tissue eosinophilia and levels of granulocyte macrophage colony-stimulating factor, interleukin (IL)-2, IL-4, IL-5, and IL-13. Considering the previously demonstrated anti-inflammatory effects of anti-IgE therapy, along with results from a small study showing continued benefit after discontinuation of long-term treatment, a larger study to assess its effect on markers of airway remodeling is underway.
Asunto(s)
Remodelación de las Vías Aéreas (Respiratorias)/efectos de los fármacos , Anticuerpos Antiidiotipos/uso terapéutico , Asma/tratamiento farmacológico , Animales , Anticuerpos Antiidiotipos/efectos adversos , Asma/inmunología , Asma/patología , Humanos , Hipersensibilidad/inmunologíaRESUMEN
The prevalence of asthma and costs of its care have been continuously increasing, but novel therapeutic options to treat this inflammatory disease have not been brought to the US market. Current therapies such as inhaled steroids, long-acting beta-agonist bronchodilators, antihistamines and immunomodulators may control the symptoms of allergic asthma but fail to modify the underlying disease. Excessive use of steroids and other immunosuppresents alter the patient's quality of life, produce undesirable toxicities, and increase the risk of other pathologies such as diabetes. Hence novel therapeutic options to manage asthma are desirable. In the present review, we have discussed the role of the polyol pathway enzyme aldose reductase (AR) in the amplification of allergic airway inflammation. Recent studies have indicated that AR inhibition prevents the NF-κB-dependent generation of pro-inflammatory cytokines and chemokines in mouse models of allergic airway inflammation indicating the potential use of AR inhibition as a novel tool to control allergic responses. Since orally available AR inhibitors have already undergone phase III clinical trials for diabetic neuropathy and appear to have a manageable side effects profile, they could be readily developed as potential new drugs for the treatment of asthma and related complications.
Asunto(s)
Aldehído Reductasa/antagonistas & inhibidores , Asma/tratamiento farmacológico , Aldehído Reductasa/metabolismo , Animales , Antiinflamatorios/uso terapéutico , Asma/epidemiología , Asma/inmunología , Humanos , Inflamación/tratamiento farmacológico , Inflamación/inmunología , Ratones , FN-kappa B/metabolismo , Sistema Respiratorio/enzimología , Sistema Respiratorio/inmunologíaRESUMEN
We demonstrate a first simultaneous measurement of both the refractive index and the attenuation coefficient (defined as the sum of the scattering and absorption coefficients) of highly turbid milk and milk-cream mixtures. We achieve this by observing the real-time reflectance profile of a divergent laser beam made incident on the surface of the milk sample. The experiments were carried out on commercial milk samples with fat volume concentrations of 0.5 or less, 1.6, and 3.3%, and on milk-cream mixtures with fat volume concentrations of 10 and 33.3%, without any dilutions of these samples. We find that the reflectance data are well described, for the first time without any empirical fit-parameters, by Fresnel theory that correctly includes the effect of angle-dependent penetration into the turbid medium on the total internally reflected signal. Therefore, our method provides the most accurate determination to date of the refractive index and attenuation coefficient of milk and milk-cream mixtures. Our sensor is compact, portable, and inexpensive.
Asunto(s)
Algoritmos , Leche/química , Refractometría/métodos , Absorción , Animales , Nefelometría y Turbidimetría , Reproducibilidad de los Resultados , Dispersión de RadiaciónRESUMEN
We demonstrate a first simultaneous measurement of the real and imaginary parts of the refractive index of a highly turbid medium by observing the real-time reflectance profile of a divergent laser beam made incident on the surface of the turbid medium. We find that the reflectance data are well described by Fresnel theory that correctly includes the effect on total internal reflection of angle-dependent penetration into the turbid medium.
RESUMEN
The asthmatic response to the common cold is highly variable, and early characteristics that predict worsening of asthma control following a cold have not been identified. In this prospective multicentric cohort study of 413 adult subjects with asthma, the mini-Asthma Control Questionnaire (mini-ACQ) was used to quantify changes in asthma control and the Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) to measure cold severity. Univariate and multivariable models were used to examine demographic, physiological, serological and cold-related characteristics for their relationship to changes in asthma control following a cold. Clinically significant worsening of asthma control was observed following a cold (mean+/-SD increase in mini-ACQ score of 0.69+/-0.93). Univariate analysis demonstrated that season, centre location, cold duration and cold severity measurements were all associated with a change in asthma control. Multivariable analysis of the covariates available within the first 2 days of cold onset revealed that the day 2 and cumulative sum of day 1 and 2 WURSS-21 scores were significant predictors of the subsequent changes in asthma control. In asthmatic subjects, cold severity within the first 2 days can be used to predict subsequent changes in asthma control. This information may help clinicians prevent deterioration in asthma control following a cold.
Asunto(s)
Asma/diagnóstico , Asma/fisiopatología , Resfriado Común/complicaciones , Corticoesteroides/uso terapéutico , Adulto , Asma/etiología , Estudios de Cohortes , Femenino , Humanos , Masculino , Persona de Mediana Edad , Análisis Multivariante , Estudios Prospectivos , Calidad de Vida , Riesgo , Encuestas y Cuestionarios , Resultado del TratamientoRESUMEN
A series of 4-(2-(bis(4-fluorophenyl)methoxy)ethyl)-(substituted benzyl) piperidines with substituents at the ortho and meta positions in the aromatic ring of the N-benzyl side chain were synthesized and their affinities and selectivities for the dopamine transporter (DAT), serotonin transporter (SERT), and norepinephrine transporter (NET) were determined. One analogue, 4-(2-(bis(4-fluorophenyl)methoxy)ethyl)-1-(2-trifluoromethylbenzyl)piperidine (the C(2)-trifluoromethyl substituted compound), has been found to act as an allosteric modulator of hSERT binding and function. It had little affinity for any of the transporters. Several compounds showed affinity for the DAT in the low nanomolar range and displayed a broad range of SERT/DAT selectivity ratios and very little affinity for the NET. The pharmacological tools provided by the availability of compounds with varying transporter affinity and selectivity could be used to obtain additional information about the properties a compound should have to act as a useful pharmacotherapeutic agent for cocaine addiction and help unravel the pharmacological mechanisms relevant to stimulant abuse.
Asunto(s)
Compuestos de Bencidrilo/síntesis química , Compuestos de Bencidrilo/farmacología , Piperazinas/síntesis química , Piperazinas/farmacología , Piperidinas/química , Piperidinas/síntesis química , Piperidinas/farmacología , Proteínas de Transporte de Serotonina en la Membrana Plasmática/efectos de los fármacos , Regulación Alostérica/efectos de los fármacos , Compuestos de Bencidrilo/química , Unión Competitiva , Proteínas de Transporte de Dopamina a través de la Membrana Plasmática/efectos de los fármacos , Humanos , Estructura Molecular , Proteínas de Transporte de Noradrenalina a través de la Membrana Plasmática/efectos de los fármacos , Piperazinas/química , Proteínas de Transporte de Serotonina en la Membrana Plasmática/química , Estereoisomerismo , Relación Estructura-ActividadRESUMEN
In an effort to identify orally bioavailable factor Xa inhibitors, two isoxazolines libraries were prepared to scan for novel P1 ligands. From this work, 4-chloro-3-aniline was identified as a novel and potent benzamidine mimic.
Asunto(s)
Técnicas Químicas Combinatorias , Inhibidores del Factor Xa , Isoxazoles/síntesis química , Animales , Benzamidinas/química , Inhibidores Enzimáticos/síntesis química , Humanos , Isoxazoles/farmacología , Imitación Molecular , Relación Estructura-ActividadRESUMEN
The field of cysteinyl leukotriene research has moved forward considerably in the past two years. Significant recent advances have been made in three areas: genetic control of the cysteinyl leukotriene response, in which alterations in both the promoter region and in transcribed mRNA have been described; the mechanisms by which cysteinyl leukotrienes promote the development of inflammation; and extensions in the clinical arena that support broader positioning of leukotriene modifiers in the therapy of asthma and allergic diseases.
Asunto(s)
Antiasmáticos/uso terapéutico , Asma/tratamiento farmacológico , Antagonistas de Leucotrieno/uso terapéutico , Leucotrienos/genética , Leucotrienos/fisiología , Animales , Antiasmáticos/farmacología , Humanos , Antagonistas de Leucotrieno/farmacologíaRESUMEN
The anti-inflammatory cytokine interleukin (IL)-10 suppresses inducible nitric oxide synthase (iNOS); therefore, NO production should increase in the absence of IL-10. Production of NO (as nitrite) by bronchoalveolar lavage cells of IL-10 knockout ((-/-)) mice was assessed after ovalbumin sensitization and airway challenge (S/C) and was compared with the IL-10-sufficient, wild-type (WT) C57Bl6. Eosinophil recruitment occurred in S/C WT and IL-10(-/-) mice, suggesting allergic airway inflammation. Alveolar macrophages (per g mouse) were unchanged (approximately 3x10(4) cells) with the exception of a doubling in the S/C IL-10(-/-) mice (approximately 6x10(4) cells, P<0.05). NO production (per million cells) was doubled in cells from S/C IL-10(-/-) (15.3 microM) mice compared with WT (7.6 microM, P<0.05). Inhibition of iNOS by L-N(5)-(1-iminoethyl)-ornithine reduced NO production in all S/C mice, confirming that the increase was a result of up-regulation of iNOS. We conclude that IL-10 is a critical cytokine regulating iNOS in murine airway cells and that its absence can lead to up-regulation of iNOS and development of allergic airway inflammation.
Asunto(s)
Interleucina-10/fisiología , Óxido Nítrico/biosíntesis , Ornitina/análogos & derivados , Sistema Respiratorio/metabolismo , Aerosoles , Animales , Biomarcadores , Líquido del Lavado Bronquioalveolar/citología , Recuento de Células , Células Cultivadas , Inhibidores Enzimáticos/farmacología , Eosinofilia/etiología , Eosinofilia/inmunología , Inmunización , Interleucina-10/deficiencia , Interleucina-10/genética , Pulmón/enzimología , Pulmón/inmunología , Macrófagos Alveolares/fisiología , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Óxido Nítrico Sintasa/antagonistas & inhibidores , Óxido Nítrico Sintasa/genética , Óxido Nítrico Sintasa/metabolismo , Óxido Nítrico Sintasa de Tipo II , Nitritos/análisis , Ornitina/farmacología , Ovalbúmina/administración & dosificación , Ovalbúmina/inmunología , ARN Mensajero/biosíntesis , Sistema Respiratorio/inmunología , Organismos Libres de Patógenos EspecíficosRESUMEN
The objective of this study was to determine whether initial maintenance therapy for the treatment of inflammation and bronchoconstriction associated with persistent asthma is more effective with a combination product (100 microg of fluticasone propionate and 50 microg of salmeterol [FSC]) administered twice daily through the Diskus device (GlaxoWellcome, Research Triangle Park, NC) or with montelukast at 10 mg once daily. A 12-wk, randomized, double-blind, double-dummy, multicenter study was conducted with 423 patients 15 yr of age and older with asthma and who were symptomatic while receiving short-acting beta(2)-agonists alone. At end point, FSC resulted in significantly greater increases in morning predose FEV(1) (0.54 +/- 0.03 vs. 0.27 +/- 0.03 L), morning peak expiratory flow (PEF) (89.9 +/- 6.7 vs. 34.2 +/- 4.7 L/min), evening PEF (69.9 +/- 5.8 vs. 31.1 +/- 4.5 L/min), the percentage of symptom-free days (48.9 +/- 2.9 vs. 21.7 +/- 2.5%), the percentage of rescue-free days (53.0 +/- 2.8 vs. 26.2 +/- 2.5%), and the percentage of nights with no awakenings (23.0 +/- 2.5 vs. 15.5+/-2.4%) compared with montelukast (p < or = 0.001, all comparisons). FSC significantly reduced asthma symptom scores (-1.0 +/- 0.1 vs. -0.6 +/- 0.1), rescue albuterol use (-3.3 +/- 0.2 vs. -1.9 +/- 0.2 puffs/d), and the number of exacerbations (0 vs. 11) compared with montelukast (p < 0.001). Both treatments were well tolerated. In summary, treatment of the two main components of asthma (inflammation and bronchoconstriction) with fluticasone propionate and salmeterol in a combination product was a more effective initial maintenance treatment strategy than treatment with montelukast, a single-mediator antagonist.
Asunto(s)
Acetatos/uso terapéutico , Agonistas Adrenérgicos beta/uso terapéutico , Albuterol/análogos & derivados , Albuterol/uso terapéutico , Androstadienos/uso terapéutico , Antiasmáticos/uso terapéutico , Antiinflamatorios/uso terapéutico , Asma/tratamiento farmacológico , Quinolinas/uso terapéutico , Adolescente , Adulto , Anciano , Ciclopropanos , Método Doble Ciego , Quimioterapia Combinada , Femenino , Fluticasona , Humanos , Masculino , Persona de Mediana Edad , Xinafoato de Salmeterol , SulfurosRESUMEN
Inflammation is a critical component of asthma. Drugs that control asthma generally reduce the degree of airway inflammation. There is theoretical controversy surrounding the effects of beta(2)-agonists on airway inflammation, with some studies suggesting an anti-inflammatory effect, and others predicting a proinflammatory influence. We conducted a double-blind, placebo-controlled, crossover study of the effect of the long-acting beta(2)-agonist salmeterol on airway inflammation induced by segmental allergen challenge (SAC). We studied 13 allergic asthmatics controlled with as needed inhaled short-acting beta(2)-agonists alone, and used bronchoalveolar lavage 5 min and 48 h after SAC to assess airway inflammation, and the effects of salmeterol on this process. Salmeterol therapy improved FEV(1), but had no significant effect on the immediate or late cellular response to SAC. One measure of superoxide production was reduced, and interleukin-4 (IL-4) was reduced in baseline samples, but other indices of airway inflammation were unchanged by salmeterol therapy. We conclude that salmeterol therapy alone does not meaningfully reduce airway inflammation induced by SAC, but equally importantly, does not result in amplified inflammation.
Asunto(s)
Agonistas Adrenérgicos beta/administración & dosificación , Albuterol/análogos & derivados , Albuterol/administración & dosificación , Alérgenos , Asma/tratamiento farmacológico , Hiperreactividad Bronquial/diagnóstico , Administración por Inhalación , Adulto , Análisis de Varianza , Asma/complicaciones , Asma/diagnóstico , Biomarcadores/análisis , Hiperreactividad Bronquial/complicaciones , Pruebas de Provocación Bronquial , Líquido del Lavado Bronquioalveolar/citología , Broncoscopía , Estudios Cruzados , Método Doble Ciego , Femenino , Humanos , Masculino , Neumonía/complicaciones , Neumonía/tratamiento farmacológico , Probabilidad , Valores de Referencia , Pruebas de Función Respiratoria , Xinafoato de Salmeterol , Resultado del TratamientoRESUMEN
Evidence supporting increased nitric oxide (NO) in asthma is substantial, although the cellular and molecular mechanisms leading to increased NO are not known. Here, we provide a clear picture of the events regulating NO synthesis in the human asthmatic airway in vivo. We show that human airway epithelium has abundant expression of NO synthase II (NOSII) due to continuous transcriptional activation of the gene in vivo. Individuals with asthma have higher than normal NO concentrations and increased NOSII mRNA and protein due to transcriptional regulation through activation of Stat1. NOSII mRNA expression decreases in asthmatics receiving inhaled corticosteroid, treatment effective in reducing inflammation in asthmatic airways. In addition to transcriptional mechanisms, post-translational events contribute to increased NO synthesis. Specifically, high output production of NO is fueled by a previously unsuspected increase in the NOS substrate, l -arginine, in airway epithelial cells of asthmatic individuals. Finally, nitration of proteins in airway epithelium provide evidence of functional consequences of increased NO. In conclusion, these studies define multiple mechanisms that function coordinately to support high level NO synthesis in the asthmatic airway. These findings represent a crucial cornerstone for future therapeutic strategies aimed at regulating NO synthesis in asthma.
Asunto(s)
Asma/metabolismo , Óxido Nítrico/biosíntesis , Procesamiento Proteico-Postraduccional/inmunología , Transcripción Genética/inmunología , Adulto , Empalme Alternativo , Arginina/metabolismo , Asma/enzimología , Asma/inmunología , Bronquios/enzimología , Bronquios/metabolismo , Líquido del Lavado Bronquioalveolar/inmunología , Proteínas de Unión al ADN/metabolismo , Células Epiteliales/enzimología , Células Epiteliales/metabolismo , Femenino , Fluocinolona Acetonida/análogos & derivados , Fluocinolona Acetonida/farmacología , Humanos , Interferón gamma/metabolismo , Janus Quinasa 1 , Masculino , Nitratos/metabolismo , Óxido Nítrico Sintasa/antagonistas & inhibidores , Óxido Nítrico Sintasa/biosíntesis , Óxido Nítrico Sintasa/genética , Óxido Nítrico Sintasa de Tipo II , Proteínas Tirosina Quinasas/metabolismo , ARN Mensajero/antagonistas & inhibidores , Especies Reactivas de Oxígeno/metabolismo , Factor de Transcripción STAT1 , Transactivadores/metabolismo , Tirosina/análogos & derivados , Tirosina/metabolismoRESUMEN
STUDY OBJECTIVE: This study aimed to establish whether the outpatient management of patients presenting with an asthma exacerbation to the emergency department (ED) was in compliance with the 1992 guidelines of the "International Consensus Report on the Diagnosis and Management of Asthma." DESIGN: Prospective, observational study using a researcher-administered questionnaire. SETTING: University tertiary referral ED. PATIENTS: Convenience sample of asthmatics (aged 18 to 54 years) presenting for asthma treatment between July 1, 1997, and June 30, 1998. RESULTS: Eighty-five asthmatic patients were enrolled. Of these, 34 patients (40%) smoked, 53 patients (62%) were undertreated with medication when compared to the consensus guidelines, and 74 patients (87%) had no written "plan of action." During an asthma attack, 9 patients (11%) did not use a bronchodilator as first-line action and 76 patients (89%) did not commence or increase the use of an inhaled steroid. Forty-nine patients (58%) did not know that bronchospasm occurred in asthma, and 53 patients (62%) did not know that bronchial swelling occurred. Twenty-six patients (31%) thought short-acting bronchodilator drugs were asthma preventers. Sixty-two patients (73%) could not adequately define peak expiratory flow (PF), 41 patients (48%) did not own a PF meter, and only 8 patients (9%) determined their PF daily. Fifty-three patients (62%) were reviewed by a physician once a year or less, and 18 patients (21%) noted family and friends as their only source of asthma education. CONCLUSIONS: The outpatient management of most asthma patients presenting to the ED did not comply with the consensus guidelines, and asthma knowledge was poor.
Asunto(s)
Asma/terapia , Servicio de Urgencia en Hospital/normas , Adhesión a Directriz , Guías de Práctica Clínica como Asunto , Adolescente , Adulto , Femenino , Conocimientos, Actitudes y Práctica en Salud , Hospitales Universitarios , Humanos , Masculino , Persona de Mediana Edad , Educación del Paciente como Asunto , Pennsylvania , Estudios Prospectivos , Índice de Severidad de la EnfermedadRESUMEN
Respiratory syncytial virus (RSV) and adenovirus (Advs) serotype 3 (Adv3) and 7h (Adv7h) are associated with mild to severe respiratory infection and are indistinguishable during the acute phases of the illnesses. However, outcome and long-term prognosis are different with both infections. RSV infection is associated with later development of asthma, and Adv, mainly Adv7h, with severe lung damage, bronchiectasis, and hyperlucent lung. We hypothesized that this difference could be partly due to different immune responses induced by these viruses. To test this hypothesis we quantified TCD4+, TCD8+, and BCD19+ expressing the interleukin-2 receptor-alpha chain (CD25) and interferon-gamma (IFN-gamma), interleukin (IL)-10, and IL-4 in the supernatant of peripheral blood mononuclear cells (PBMC) from school children infected in vitro with and without RSV, Adv7h, and Adv3 and after phytohemagglutinin (PHA) stimulation in the presence or absence of these viruses at a multiplicity of infection (MOI) of 1. PBMC from every child produced more IL-10 (p = 0.05) when infected with RSV than with Advs and noninfected control, and Adv induced more (p = 0.05) IFN-gamma than did RSV and control. The IL-10/IFN-gamma ratio was significantly higher (p = 0.05) in RSV-infected and significantly lower (p = 0.05) in Adv-infected PBMC, than in noninfected cells. PHA-stimulated BCD19+ RSV- infected cells expressed more (p = 0.05) IL-2R than did Adv-infected cells. These results suggest that Advs induce a Th-1-type immune response that is not seen with RSV. These patterns persist despite intersubject variation in the absolute quantity of cytokine produced.
Asunto(s)
Adenovirus Humanos/fisiología , Citocinas/metabolismo , Leucocitos Mononucleares/metabolismo , Virus Sincitial Respiratorio Humano/fisiología , Infecciones por Adenovirus Humanos/inmunología , Células Cultivadas , Niño , Humanos , Interferón gamma/metabolismo , Interleucina-10/metabolismo , Interleucina-4/metabolismo , Leucocitos Mononucleares/inmunología , Leucocitos Mononucleares/virología , Activación de Linfocitos , Subgrupos Linfocitarios/metabolismo , Receptores de Interleucina-2/metabolismo , Infecciones por Virus Sincitial Respiratorio/inmunologíaRESUMEN
Asthma is a syndrome characterized by variable airflow limitation, airway hyperresponsiveness and airway inflammation. Considering asthma in aggregate, it is clear that a number of distinct mechanisms underlie the development of this disorder. In some patients, the mechanistic distinctions can be clearly drawn, and important therapeutic insights can be gained. In other patients, several mechanisms may coexist, or it may be impossible to separate them with current methods and technology. To distinguish subsets of asthma is more than an academic exercise. For both clinicians and asthma researchers, it is valuable to distinguish asthma subtypes as clearly as possible. Clinicians strive to prescribe the most effective, most safe, and most cost effective therapy possible, and understanding asthma subsets and their underlying mechanistic differences can substantively facilitate achieving that objective. Asthma research is often limited by significant, and sometimes dramatic intersubject variability. It is likely that at least some of that variability may arise from the (unrecognized) mechanistic heterogeneity of asthma. Better definition and selection of more homogeneous subsets of asthma may then lead to greater statistical power, and more definitive conclusions from asthma investigations.
RESUMEN
BACKGROUND: Previous trials demonstrated the effectiveness of the leukotriene receptor antagonist zafirlukast in patients with mild-to-moderate asthma. OBJECTIVES: We sought to assess the efficacy and safety of zafirlukast and its effect on patients' quality of life (QOL) during a 13-week, double-blind, placebo-controlled, multicenter trial in adults and adolescents with moderate reversible airflow obstruction. METHODS: Patients (age range, 12 to 68 years) with total daytime asthma symptoms scores of 10 or greater over 7 consecutive days (maximum, 21/wk), FEV1 45% or greater but less than or equal to 80% of predicted value (>/=6 hours after beta2 -agonist), and reversible airway disease were randomized to 20 mg zafirlukast twice daily (nZ = 231) or placebo twice daily (nP = 223). Efficacy was assessed from changes in daytime and nocturnal symptoms, beta2 -agonist use, nasal congestion score, and pulmonary function. QOL was evaluated with a disease-specific Asthma Quality of Life Questionnaire. Safety was determined from adverse event information and clinical laboratory test results. RESULTS: Zafirlukast was significantly (P <.001) more effective than placebo, with reductions from baseline in the daytime asthma symptoms score (-23%), nighttime awakenings with asthma (-19%), and beta2 -agonist use (-24%) and improvements from baseline in morning (+25 L/min) and evening (+18 L/min) peak expiratory flow rates. Compared with placebo, zafirlukast significantly (P =.018) improved scores for QOL domains (activity limitations, symptoms, emotional function, and exposure to environmental stimuli) and overall QOL, with a significantly greater proportion of zafirlukast-treated patients demonstrating clinically meaningful improvements (>/=0.5-unit change from baseline; P =.037). The safety profile of zafirlukast was clinically indistinguishable from that of placebo. CONCLUSIONS: Zafirlukast is effective and well tolerated and improves QOL in the long-term treatment of patients with moderate reversible airflow obstruction.
Asunto(s)
Asma/tratamiento farmacológico , Broncodilatadores/uso terapéutico , Enfermedades Pulmonares Obstructivas/tratamiento farmacológico , Compuestos de Tosilo/uso terapéutico , Adolescente , Adulto , Anciano , Broncodilatadores/efectos adversos , Niño , Método Doble Ciego , Femenino , Humanos , Indoles , Masculino , Persona de Mediana Edad , Fenilcarbamatos , Calidad de Vida , Sulfonamidas , Compuestos de Tosilo/efectos adversosRESUMEN
Zafirlukast is an orally active and selective cysteinyl leukotriene (cysLT) receptor antagonist. In humans, zafirlukast antagonized the effects of exogenously administered LTD4 and cysLTs released endogenously in response to physical and chemical stimuli. Zafirlukast antagonized LTD4-induced bronchoconstriction, with effects still evident 12 h after drug administration. In clinical models of asthma, zafirlukast inhibited bronchospasm after allergen or exercise challenge in patients with asthma. In multicenter trials in patients with chronic, stable asthma, zafirlukast reduced asthma symptoms, decreased as-needed beta-agonist use, and improved pulmonary function without increasing the number of adverse events. Zafirlukast also exhibited evidence of an anti-inflammatory effect in the lung in preliminary studies involving segmental antigen challenge. The results from these clinical trials demonstrate that zafirlukast is effective and safe for the prophylactic treatment of asthma.